Form 4: Amgen Director Michael V. Drake Reports Acquisition of Common Stock

Director Michael V. Drake reports acquiring 719 shares of Amgen common stock on May 31, 2024, through vested Restricted Stock Units (RSUs) under the company's director incentive program.

Summary

• On May 31, 2024, Michael V. Drake, a director at Amgen Inc., acquired 719 shares of common stock.
• The acquisition was made through the vesting of Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Director Incentive Program.
• The RSUs vested immediately and are payable in shares of Amgen's common stock on a one-to-one basis.
• Drake directly owns 3,174.7662 shares of Amgen common stock following the transaction, which includes 92 Dividend Equivalents (DEs).
• The price per share at the time of acquisition was $0, as the shares were obtained through vested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of an insider transaction, which doesn't inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting of RSUs aligns the director's interests with those of the shareholders.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their holdings in the company's stock.

Comparison to Industry Standards

• Director compensation in the form of stock and options is a common practice among publicly traded companies, including Amgen's peers in the biotechnology and pharmaceutical industries such as Johnson & Johnson, Pfizer, and Merck.
• The Amgen Inc. 2009 Director Incentive Program is similar to equity compensation plans offered by other large corporations to align the interests of directors with those of shareholders.
• The reporting requirements under Section 16(a) of the Securities Exchange Act of 1934 are standard for all insiders of publicly traded companies in the United States.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with theirs.

Key Dates